In August 2021, Dicot released the results of its latest animal study on healthy rats, which concluded that the drug candidate LIB-01 has a longer effect on erection than other drugs on the market today, and that the effect increases over time.

The company is now publishing a new study, in collaboration with the French contract laboratory Pelvipharm, which includes rats with an underlying disease - diabetes. Due to the disease, these rats have a proven erectile dysfunction. In the established in vivo animal model, the study showed that Dicot's drug candidate significantly improved erection compared to vehicle at all measured parameters. The effect occurred after repeated dosing for three days and was measured 24 hours after the last administration.

Up to 50-60 percent of all men with diabetes will experience erectile dysfunction and is believed to develop this ten to fifteen years earlier than men without diabetes.

"This is a big leap forward for us. The results indicate that Dicot's drug candidate can provide treatment to many of the patients who have disease-related erection problems. These results are rare among new drugs that have been tested in this type of animal study and therefore very promising ", says Göran Beijer, CEO of Dicot.

"This is an important step on the way to finding an improved treatment for patients who do not respond well to the products on the market today," comments Professor Francois Guiliano,  founder of Pelivpharm.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.

This information is such that Dicot AB is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on October 14, 2021.